18 39

Cited 52 times in

Detection of Phenolic Glycolipid I of Mycobacterium leprae in Sera from Leprosy Patients before and after Start of Multidrug Therapy

 Sang-Nae Cho ; Roland V. Cellona ; Patrick J. Brennan ; Joo-Deuk Kim ; Gerald P. Walsh ; Esterlina V. Tan ; Rodolfo M. Abalos ; M. Victoria F. Balagon ; Tranquilino T. Fajardo, Jr. ; Laarni G. Villahermosa 
 Clinical and Diagnostic Laboratory Immunology, Vol.8(1) : 138~142, 2001 
Journal Title
 Clinical and Diagnostic Laboratory Immunology 
Issue Date
A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay (ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1%) of 29 patients with a BI of 4.0 or above and in 15 (68.2%) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I in serum declined rapidly by about 90% 1 month after the start of multidrug therapy. This study showed clearly that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in the assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemotherapy.
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Microbiology
Yonsei Authors
사서에게 알리기
Files in This Item:
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.